The 2.3% device tax is more complex than you realize; Poll: Consumers demand more device safety oversight;

@FierceMedDev: Stryker Stent May Not Be Worth the Stroke Risks, FDA Says via @BloombergNewsItem | Follow @FierceMedDev

> Experts advise medical device companies that implementing the 2.3% excise tax will be more complex than people think. Report

> PA-based ClearCount Medical Solutions has launched a new addition to its radio frequency technology system that prevents surgical sponges and towels from getting left inside a patient. Item

> Kips Bay Medical ($KIPS) has tapped CFO Scott Kellen to also be COO. Kips Bay release

> Meridian Bioscience's ($VIVO) Bioline unit has received clearance from the Therapeutic Goods Administration in Australia for its illumigene Group B Streptococcus test. This approval comes on the heels of the recent FDA clearance. Meridian release

> Medical products company Abbott ($ABT) has named the independent, research-based pharmaceutical company it will spin off by the end of this year: AbbVie. Story

And Finally... Most Americans want strong medical device safety oversight, according to a new Consumer Reports poll. Release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.